ALEXANDRIA, Va., Sept. 17 -- United States Patent no. 12,415,856, issued on Sept. 16, was assigned to Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.).
"EGFR x CD28 multispecific antibodies" was invented by Dimitris Skokos (New York), Andrew J. Murphy (Tarrytown, N.Y.), George D. Yancopoulos (Yorktown Heights, N.Y.), Chia-yang Lin (Scarsdale, N.Y.) and Lauric Haber (Rye Brook, N.Y.).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides multispecific antibodies that bind to EGFR and CD28 (EGFRxCD28) as well as anti-EGFR antibodies. Such antibodies may be combined with a further therapeutic agent such as an anti-PD1 antibody. Methods for treating cancers (e.g., EGFR-expressing cancer) by...